The Next Study That Tracks Symptoms and Function Together

1. Research Question: From Average Differences to Change Paths

Current tools observe different time windows. The 2016 criteria structure painful sites and symptoms such as fatigue and waking unrefreshed, while the FIQR asks about function, overall impact, and symptoms over the past seven days. Quantitative sensory testing (QST) records responses to controlled stimuli at the time of testing. ^{[1, 2, 4]}

Each measure is necessary, but comparing only total scores and group averages while leaving these different clocks unaligned makes it difficult to know when symptoms change after activity within one person and when that change reaches function. The evidence reviewed here contains no time-linked activity and symptom data, so it cannot establish the sequence of pre-activity state, onset, magnitude, duration, and recovery. ^{[1, 2, 4]}

The central question is therefore not, “Which test best proves fibromyalgia?” It is, “Within individuals, in what sequence do activity, sleep, pain, fatigue or energy, function, and QST responses change together or separately, and how much do those paths differ across people and treatment contexts?” Temporal precedence can narrow a hypothesis, but it does not by itself establish a cause. ^{[1, 2, 3, 4, 5]}

2. Whom and Where Should the Study Observe?

The population should be defined as adults who meet the 2016 criteria after clinical evaluation, with recruitment routes and care settings recorded. The self-report version of the criteria should not substitute for individual diagnosis, and the requirement that pain and symptoms have persisted at a similar level for at least three months should be read only as an entry condition, not as evidence that no later change occurs. ^[1]

Comorbid conditions should be treated as interpretive context rather than grounds for blanket exclusion. The 2016 criteria also state that a fibromyalgia diagnosis does not exclude the presence of other clinically important illnesses. Situations requiring clinical assessment should nevertheless be routed separately from research measurement so that new or changing clinical findings are not handled only as study variables. ^[1]

To distinguish heterogeneity, the study should include participants with varied baseline pain distribution, fatigue or energy, sleep problems, functional levels, treatment status, and comorbid conditions, and report the numbers in each recruitment stratum. If enrollment is concentrated by sex, age, or care site, or retains only people able to use the devices, that scope should be stated when interpreting results. Sample size should not be fitted to a desired number of subgroups; it should be calculated from valid primary effects and the repeated-measures structure, using pilot estimates of variability, missingness, and attrition.

3. Placing Several Time Windows on One Clock

The key is not to repeat every measure at the same frequency, but to record the timing of distinct measurements accurately on a shared clock. Pain, fatigue, waking refreshed, and states before and after activity should be captured in brief, event-near diaries; activity and sleep-wake patterns should be recorded as continuously as feasible; and the FIQR should preserve the instrument's past-seven-day window. ^{[2, 3]}

The evidence reviewed here cannot determine the optimal number of daily diary entries or duration of observation. A short feasibility phase should first examine response burden, missed entries, weekday and weekend coverage, wear time, and symptom variability. Frequency, allowed response windows, minimum valid days, and observation length should then be fixed before the main analysis. Participants with extensive missing data should not be silently excluded; the timing and reasons for missingness should also be retained as time data.

QST is not a measure to be administered daily like a diary. It should use the same stimuli, instructions, sites, equipment, rest periods, and interpretive rules at baseline and at prespecified follow-up points, while recording sleep, activity, symptoms, and treatment exposure before the test. The exact retest interval should be fixed after the feasibility phase assesses burden and repeat-testing effects, and the result should not be used for individual diagnosis or as a verdict on whether pain is genuine. ^{[4, 5]}

4. What Should Be Measured Together but Not Read as Substitutes?

The symptom diary should ask separately about pain intensity and distribution, fatigue, waking unrefreshed, cognitive difficulty, pre-activity state, and change after activity. No item should stand in for another. For post-activity change, activity type, duration, perceived intensity, start time, and the onset, magnitude, duration, and recovery of symptom change should be linked to the same event whenever possible. These questions do not presume a universal worsening path; they are records intended to test whether such paths exist. ^{[1, 2]}

Activity measurement should separate raw device data from derived values such as steps, acceleration, and active and inactive intervals, while retaining device type, wear location, wear time, and rules for detecting non-wear. Reported difficulty with activities should remain a separate FIQR function measure. Less movement is not identical to functional impairment, and more movement does not mean that symptoms are mild. ^[2]

Sleep should not be collapsed into one value either. In a study of 113 adults with comorbid insomnia and fibromyalgia, sleep diaries, actigraphy, and polysomnography did not give the same baseline estimates or detect post-treatment change in the same way. The treatment-change analysis was limited in particular to a 15-person cognitive behavioral therapy for insomnia (CBT-I) subgroup, so the next study should keep diary-reported sleep experience and actigraphic sleep-wake estimates as separate variables and analyze discordance rather than treating it as a defect. ^[3]

5. Treatment Context Is a Timeline, Not an Effect Estimate

Medication starts, stops, and dose changes; rehabilitation, exercise, and psychological-therapy sessions; sleep interventions; acute illness; and major life changes should be dated and timed as precisely as feasible. Recording exposure timing, whether a change was planned, concurrent interventions, and adherence, rather than treatment name alone, makes it possible at least to order measurement changes before or after treatment. ^{[3, 4]}

Differences before and after treatment in this observational study must not be called effects. Treatment may not be randomized, and rival explanations remain, including reverse causation when worsening symptoms lead to treatment changes, regression to the mean, expectations, seasonality, and diary reactivity. Treatment context should initially be used as a time-varying covariate and stratification variable; an effect comparison should be prespecified only when supported by a separate design and sample-size rationale. ^{[3, 4]}

The QST review proposed that before-and-after intervention QST is scarce and should be distinguished by treatment type, but that is not a finding that QST change mediates or predicts treatment response. Symptoms or function may improve while QST remains unchanged, and the reverse is also possible. These rival models should be retained together. Change in one measure does not determine the validity of another. ^{[4, 5]}

6. Analysis Plan: Sequence Within People and Differences Between People

The first unit of analysis should be repeated observations within individuals rather than the group average. All data should be aligned to a common clock while preserving their original windows, and several candidate lags should be used to explore relations among activity and sleep intervals, symptom change, and function on the next day or during the next week. Lags and primary outcomes used for confirmatory analysis should be fixed after the feasibility phase and before viewing those results.

The model should allow person-specific baselines and slopes and separate within-person effects from between-person differences. Subgroups should not be assumed to be fixed types from the outset; discovery clustering and a replication sample should be separated. QST protocol, recruitment site, treatment exposure, comorbid conditions, device wear, and missingness should be recorded together to test whether observed paths are tied to a particular method or sample. ^{[1, 3, 4, 5]}

At least three rival explanations should be compared: a model in which sleep change precedes next-day symptoms, a model in which the relation between activity and symptoms varies with baseline function or treatment context, and a model in which measurement burden and missingness create apparent worsening. Reverse-direction and simultaneous-change models should also remain in consideration. A better-fitting path alone must not be used to declare a biological cause or a universal patient type.

7. Safety, Burden, and Stopping Rules

Observation does not replace clinical care. When a participant reports new neurological signs, a rapid change in condition, or a clinical safety signal specified in advance by the research team, measurement should be paused and the participant directed to a separate clinical assessment pathway rather than automatic analysis continuing. Specific safety signals and responsibility for the response should be established through clinical and ethics review before the study starts, and study data alone should not be used to attribute them to fibromyalgia. ^[1]

Participants should be able to stop some or all diary, device, or QST procedures without giving a reason. A measure should be stopped or adjusted immediately if QST causes pain or discomfort beyond permitted limits, a device causes skin problems or disrupts sleep, or repeated questions create excessive burden. Stopping is an outcome of acceptability and safety, not a failure; its reason and timing should be retained where analytically possible rather than deleted at discretion. ^{[4, 5]}

The study also needs rules for stopping or redesigning its procedures. If valid wear time and diary response fall below prespecified criteria, QST standardization cannot be maintained across sites, or burden and attrition concentrate in a particular group, investigators should pause and revise the procedure rather than conceal the problem by expanding recruitment. Data collected before and after a revision should be distinguished, and hypotheses formed after the change should not be written as though they had been specified from the start.

8. What Would Count as Success?

Success should not be defined as finding one biomarker or a single patient type. The first questions are whether distinct measures were placed on the same time axis with sufficient accuracy and acceptability, whether enough repeated observations remain to estimate individual paths, and whether discordance and missingness can be explained without being hidden. ^{[2, 3, 4, 5]}

Results should then be reported in three layers: average tendencies that recur overall, different paths among individuals or reproducible subgroups, and relations that the current design cannot distinguish. Raw data and derivation rules, protocol deviations, analysis code, and prespecified decisions should be retained together so that discovery can be separated from confirmation and tested in another sample.

The question this design addresses is not whether pain is real. A patient's report exists before the test; the test is a tool for recording more precisely how that experience changes in relation to function. When symptoms, sleep, activity, function, QST, and treatment context are placed on one clock without being collapsed into the same phenomenon, heterogeneity becomes a testable change path rather than a label. ^{[1, 2, 3, 4, 5]}

Declarations

Author contributions (CRediT)

Baekrokdam Research Commons (BRC): Investigation, Data curation, Evidence verification, Writing – original draft, Writing – review & editing

Data availability

This article used only the public literature listed in its references. No individual patient data or separate clinical dataset was used.

Funding

No external funding.

Competing interests

The publishing organization originated at Baekrokdam Korean Medicine Clinic and has clinical and commercial interests. This article is not evidence for a particular diagnosis or treatment effect.

AI use disclosure

AI tools assisted the structuring of public-literature materials, drafting, and bilingual production. AI is not an author; BRC remains responsible for source verification, final judgments, and publication.

Ethics

Only public literature was used; no individual patient data or clinical intervention was involved. Any future human-participant research requires separate ethics review before it begins.

References

1. Wolfe F, Clauw DJ, Fitzcharles M-A, Goldenberg DL, Häuser W, Katz RL, et al. 2016 Revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria. Seminars in Arthritis and Rheumatism. 2016;46(3):319–329. doi:10.1016/j.semarthrit.2016.08.012. https://doi.org/10.1016/j.semarthrit.2016.08.012
2. Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQR): Validation and Psychometric Properties. Arthritis Research & Therapy. 2009;11(4):R120. doi:10.1186/ar2783. https://doi.org/10.1186/ar2783
3. Measuring Treatment Outcomes in Comorbid Insomnia and Fibromyalgia: Concordance of Subjective and Objective Assessments. PubMed record and abstract. PMID:26414976. The preserved record does not include author or journal metadata. Source
4. Carneiro AM, de Góes Salvetti M, Dale CS, da Silva VA. Quantitative Sensory Testing in Fibromyalgia Syndrome: A Scoping Review. Biomedicines. 2025;13(4):988. doi:10.3390/biomedicines13040988. https://doi.org/10.3390/biomedicines13040988
5. Value of Quantitative Sensory Testing in Neurological and Pain Disorders: NeuPSIG Consensus. PubMed record and abstract. PMID:23742795. The preserved record does not include author or journal metadata; this consensus is not fibromyalgia-specific. Source